Younger age and low NLR improve survival in non-small cell lung cancer patients, indicating the need for strategic management of immune checkpoint inhibitors.
Younger age and low NLR were associated with long-term survival in NSCLC patients treated with ICIs. Adenocarcinoma and switching administration may have potential clinical relevance. These findings highlight the importance of patient selection and strategic management of ICI therapy. Nevertheless, confirmation in larger prospective cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Takahara et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: